Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pancreatic polypeptide (PP) is a 36-amino acid peptide hormone secreted by PP cells in the pancreatic islets of Langerhans. It plays a crucial role in regulating digestive and metabolic processes, including inhibiting gastric emptying and biliary secretion, increasing hepatic insulin sensitivity, and suppressing appetite. PP secretion is stimulated by vagal input and hormonal signals like cholecystokinin after meals. Deficiency contributes to hepatic insulin resistance, while administration can reverse this effect without raising serum insulin levels. Elevated plasma levels are observed in certain endocrine tumors and with age, suggesting a role as a biomarker. Therapeutic strategies targeting PP signaling are explored for diabetes management and appetite control.
PP primarily acts by binding to the Y4 receptor (also known as NPY4R) to modulate digestive and metabolic processes. This includes inhibiting gastric emptying and biliary secretion, increasing insulin receptor numbers on hepatocytes, and suppressing appetite via central mechanisms.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pancreatic Polypeptide (PP).